common glp 1 agonists glp-1_analogs [TUSOM GLP-1 receptor agonists: Optimising nutritional

Speak to a healthcare professional

A., Rebello, C

Tang, G

GLP-1 agonists have emerged as a popular option for supporting weight loss, but many people wonder if they need to use these medications forever

Potentially one the most debated points regarding the GLP-1 RA guidelines is how the recommended discontinuation of these medications may impact those with confounding conditions who may truly need them for either obesity management, glycemic control and possible benefits in heart failure, and chronic renal disease

According to the group of authors, these polyagonists are in all likelihood the next step towards a cure for diabetes and obesity. Comparable to bariatric surgery The authors report on various polyagonists that are currently being researched in clinical studies and show improved efficacy with each new generation. The latest triple agonists attack both the glucose-dependent insulinotropic peptide receptor (GIPR) and the receptors for glucagon-like peptide 1 (GLP1) and glucagon (GCG, a hormone from the pancreas)